PBA
ALPN

Paradigm Biocapital Advisors’s Alpine Immune Sciences Inc ALPN Stock Holding History

Paradigm Biocapital Advisors’s Portfolio ALPN Stock Details ALPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-2,121,163
Closed -$84.1M – 44
2024
Q1 		$84.1M Sell
2,121,163
-1,055,580
-33% -$31.1M 2.96% 17
2023
Q4 		$60.5M Buy
3,176,743
+755,000
+31% +$10.5M 2.83% 16
2023
Q3 		$27.7M Sell
2,421,743
-2,218
-0.1% -$27.3K 1.88% 21
2023
Q2 		$24.9M Buy
2,423,961
+106,327
+5% +$959K 1.93% 20
2023
Q1 		$17.9M Hold
2,317,634
– – 1.7% 22
2022
Q4 		$17M Buy
2,317,634
+102,912
+5% +$658K 2% 19
2022
Q3 		$15.9M Buy
2,214,722
+1,387,943
+168% +$11.4M 2.13% 17
2022
Q2 		$7.04M Buy
826,779
+490,550
+146% +$4.23M 1.4% 17
2022
Q1 		$3.02M Buy
+336,229
New +$2.91M 0.8% 24

Paradigm Biocapital Advisors's ALPN Position: Q2 2024 in Review

Paradigm Biocapital Advisors sold out of Alpine Immune Sciences Inc (ALPN) in Q2 2024, closing a stake of 2,121,163 shares — an estimated $84.1M sold.

Paradigm Biocapital Advisors first reported a position in ALPN in Q1 2022 and held it in 9 quarters. The position peaked at $84.1M in Q1 2024. 0 funds tracked by Wall St. Rank hold ALPN as of Q2 2024.

  • Paradigm Biocapital Advisors reported no remaining Alpine Immune Sciences Inc position as of Q2 2024 after selling out during the quarter.
  • Paradigm Biocapital Advisors sold 2,121,163 Alpine Immune Sciences Inc shares in Q2 2024, an estimated $84.1M.
  • Paradigm Biocapital Advisors first reported a position in Alpine Immune Sciences Inc in Q1 2022 and held it in 9 quarters.
  • Paradigm Biocapital Advisors's Alpine Immune Sciences Inc position peaked at $84.1M in Q1 2024.
  • 0 funds tracked by Wall St. Rank held Alpine Immune Sciences Inc as of Q2 2024.

Based on Paradigm Biocapital Advisors's 13F filing for Q2 2024, filed 14 Aug 2024.